UnitedHealth Acquires Amedisys in $3.3 Billion Deal After Long Regulatory Battle
PorAinvest
sábado, 16 de agosto de 2025, 6:26 am ET1 min de lectura
AMED--
The DOJ initially sued to block the deal in November 2023, citing concerns that the merger would hinder access to home health and hospice services. However, UnitedHealth and Amedisys reached a settlement with the DOJ on Aug. 7, 2024, which required the companies to divest 164 home health and hospice locations in 19 states [2]. The divestiture impacts facilities with a combined annual revenue of $528 million and includes one palliative care facility [1].
The settlement also required Amedisys to pay a $1.1 million civil penalty for falsely certifying that it had provided accurate responses under the Hart-Scott-Rodino (HSR) Antitrust Improvements Act. Additionally, the proposal obligates UnitedHealth to divest an additional eight locations if it fails to obtain regulatory approval for the initial divestiture and imposes a monitor to supervise UnitedHealth's compliance and provide the divestiture buyers with the necessary assets, personnel, and relationships to compete against UnitedHealth in the overlap areas [1].
UnitedHealth will fold Amedisys into its health services division Optum, which already owns LHC Group. The acquisition will help UnitedHealth's vertical integration strategy, where it benefits from the interplay between its UnitedHealthcare insurance arm and its healthcare delivery assets [3]. The merger is expected to make UnitedHealth the largest player in the U.S. home health and hospice market.
The deal has drawn criticism from some lawmakers who argue that the settlement fails to protect competition and could lead to higher costs and reduced access to home health and hospice care. However, UnitedHealth has stated that the merger will help it keep patients healthy and improve its home health capabilities [3].
References:
[1] https://financialregnews.com/justice-department-to-require-unitedhealth-group-divestitures-in-amedisys-acquisition/
[2] https://www.theadvocate.com/baton_rouge/news/business/33-billion-deal-for-baton-rouge-based-amedisys-completed/article_875b8089-3a1a-4d38-910e-90a861ef8268.html
[3] https://www.healthcaredive.com/news/unitedhealth-amedisys-deal-closes-doj/757742/
UNH--
UnitedHealth Group has closed its $3.3 billion acquisition of home health and hospice provider Amedisys after a two-year regulatory battle. The deal marks a significant expansion of UnitedHealth's home health capabilities and makes it a serious contender in the US home health and hospice market. UnitedHealth will fold Amedisys into its health services division Optum, which already owns LHC Group.
UnitedHealth Group has completed its $3.3 billion acquisition of home health and hospice provider Amedisys, marking a significant expansion of the company's home health capabilities and positioning it as a major player in the U.S. home health and hospice market. The acquisition, which was announced on Thursday, follows a two-year regulatory battle with the U.S. Department of Justice (DOJ) [1].The DOJ initially sued to block the deal in November 2023, citing concerns that the merger would hinder access to home health and hospice services. However, UnitedHealth and Amedisys reached a settlement with the DOJ on Aug. 7, 2024, which required the companies to divest 164 home health and hospice locations in 19 states [2]. The divestiture impacts facilities with a combined annual revenue of $528 million and includes one palliative care facility [1].
The settlement also required Amedisys to pay a $1.1 million civil penalty for falsely certifying that it had provided accurate responses under the Hart-Scott-Rodino (HSR) Antitrust Improvements Act. Additionally, the proposal obligates UnitedHealth to divest an additional eight locations if it fails to obtain regulatory approval for the initial divestiture and imposes a monitor to supervise UnitedHealth's compliance and provide the divestiture buyers with the necessary assets, personnel, and relationships to compete against UnitedHealth in the overlap areas [1].
UnitedHealth will fold Amedisys into its health services division Optum, which already owns LHC Group. The acquisition will help UnitedHealth's vertical integration strategy, where it benefits from the interplay between its UnitedHealthcare insurance arm and its healthcare delivery assets [3]. The merger is expected to make UnitedHealth the largest player in the U.S. home health and hospice market.
The deal has drawn criticism from some lawmakers who argue that the settlement fails to protect competition and could lead to higher costs and reduced access to home health and hospice care. However, UnitedHealth has stated that the merger will help it keep patients healthy and improve its home health capabilities [3].
References:
[1] https://financialregnews.com/justice-department-to-require-unitedhealth-group-divestitures-in-amedisys-acquisition/
[2] https://www.theadvocate.com/baton_rouge/news/business/33-billion-deal-for-baton-rouge-based-amedisys-completed/article_875b8089-3a1a-4d38-910e-90a861ef8268.html
[3] https://www.healthcaredive.com/news/unitedhealth-amedisys-deal-closes-doj/757742/

Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios